Evidence map›Paper›PMID 24646865›Full record

ArticleRNA biology2014

Use of the computer-retargeted group II intron RmInt1 of Sinorhizobium meliloti for gene targeting.

Fernando M García-Rodríguez, Teresa Hernández-Gutiérrez, Vanessa Díaz-Prado, Nicolás Toro

Abstract read
In one paragraph

Article in RNA biology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Fernando M García-RodríguezGrupo de Ecología Genética, Estación Experimental del Zaidín; Consejo Superior de Investigaciones Científicas; Granada, Spain.
Teresa Hernández-GutiérrezGrupo de Ecología Genética, Estación Experimental del Zaidín; Consejo Superior de Investigaciones Científicas; Granada, Spain.
Vanessa Díaz-PradoGrupo de Ecología Genética, Estación Experimental del Zaidín; Consejo Superior de Investigaciones Científicas; Granada, Spain.
Nicolás ToroGrupo de Ecología Genética, Estación Experimental del Zaidín; Consejo Superior de Investigaciones Científicas; Granada, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gene-targeting vectors derived from mobile group II introns capable of forming a ribonucleoprotein (RNP) complex containing excised intron lariat RNA and an intron-encoded protein (IEP) with reverse transcriptase (RT), maturase, and endonuclease (En) activities have been described. RmInt1 is an efficient mobile group II intron with an IEP lacking the En domain. We performed a comprehensive study of the rules governing RmInt1 target site recognition based on selection experiments with donor and recipient plasmid libraries, with randomization of the elements of the intron RNA involved in target recognition and the wild-type target site. The data obtained were used to develop a computer algorithm for identifying potential RmInt1 targets in any DNA sequence. Using this algorithm, we modified RmInt1 for the efficient recognition of DNA target sites at different locations in the Sinorhizobium meliloti chromosome. The retargeted RmInt1 integrated efficiently into the chromosome, regardless of the location of the target gene. Our results suggest that RmInt1 could be efficiently adapted for gene targeting.

Indexed as

Gene TargetingIntronsAlgorithmsBase PairingBase SequenceBinding SitesChromosomes, BacterialComputational BiologyExonsNucleotide MotifsPosition-Specific Scoring MatricesSinorhizobium melilotigene targetinggroup II intronsribozymeRmInt1Sinorhizobium meliloti

Identifiers

PMID24646865
PMCPMC4075523

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.